Upregulation of cytochromes P450 2B in rat liver by orphenadrine.
1 The alkylamine drug orphenadrine (ORPH) is an inducer and inhibitor of the microsomal cytochrome P450 (CYP) system in mammals. This study evaluated the selectivity of CYP induction by ORPH in rat liver. 2 Immunoblot analysis indicated that ORPH was a selective inducer of the phenobarbitone (PB)-inducible CYP2B in rat liver. CYP2B protein was increased to approximately 14-fold of levels in untreated rat liver. By comparison PB increased CYP2B expression 40-fold. Corresponding increases in the activity of CYP2B-dependent androstenedione 16beta-hydroxylation were measured in microsomes from ORPH and PB-induced rats. 3 Northern analysis indicated that CYP2B1/2 mRNA was increased in ORPH-induced rat liver. Consistent with this finding, ORPH was found to activate a PB-responsive enhancer module in constitutive androstane receptor (CAR)-transfected Hep G2 cells. 4 Other alkylamines like troleandomycin impair CYP turnover. We tested whether ORPH induction of CYP2B may include a post-translational component. In PB-pretreated animals ORPH administration delayed the loss of CYP2B after PB withdrawal, but no evidence for altered turnover was found. 5 These studies establish ORPH as a selective inducer of CYP2B in rat liver. Induction appears to be mediated pretranslationally by CAR activation of CYP2B gene transcription. Post-translational stabilisation by an ORPH metabolite does not elicit induction. Induction of CYP2B may influence pharmacokinetic interactions involving ORPH.
Murray
Michael
M
Department of Physiology and Pharmacology, School of Medical Sciences, University of New South Wales, Sydney, NSW 2052, Australia. M.Murray@unsw.edu.au
Fiala-Beer
Eva
E
Sutton
Dylan
D
D000818:Animals; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects* / Q000235:genetics*; D003907:Dexamethasone / Q000008:administration & dosage / Q000493:pharmacokinetics; D004121:Dimethyl Sulfoxide / Q000008:administration & dosage / Q000493:pharmacokinetics; D004790:Enzyme Induction / Q000187:drug effects; D005786:Gene Expression Regulation / Q000187:drug effects / Q000502:physiology; D007274:Injections, Intraperitoneal; D008297:Male; D008862:Microsomes, Liver / Q000201:enzymology*; D009966:Orphenadrine / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics*; D010634:Phenobarbital / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics; D014176:Protein Biosynthesis / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D015854:Up-Regulation / Q000187:drug effects* / Q000502:physiology; D019324:beta-Naphthoflavone / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics
D065607:Cytochrome P-450 Enzyme Inhibitors; D019324:beta-Naphthoflavone; D003907:Dexamethasone; D003577:Cytochrome P-450 Enzyme System; D009966:Orphenadrine; D004121:Dimethyl Sulfoxide; D010634:Phenobarbital